New paper below [1].
Over the years, Mark McCarty has written some thoughtful papers on PCa, i.e. from the perspective of someone interested in the effect of dietary factors. Here, he gives advice on dealing with a PCa growth factor that has had little attention.
"Fibroblast growth factor 23 (FGF23), a hormonal regulator of phosphate and vitamin D metabolism produced primarily in bone by osteocytes and mature osteoblasts, is now known to have growth factor activity for many prostate cancers. In some of these cancers, autocrine production of FGF23 drives their proliferation. FGF23 synthesized within bone likely promotes the expansion of prostate cancer bone metastases."
We already know that excess calcium & phosphate is associated with aggressive PCa, & maybe FGF23 is the connection:
"... dietary or lifestyle factors which boost bone's production of FGF23 may encourage the ... spread of prostate cancer."
"High dietary intakes of bioavailable phosphorus and of calcium have been found to boost FGF23 levels, and this accords well with prospective epidemiology pointing to high intakes of both phosphate and calcium as risk factors for aggressive prostate cancer."
I have never been enthusiatic about a vegan diet for PCa, in that I have never seen a case made for a particular form. "Vegan" is supposed to be self-explanatory. But cancer cells like good nourishment too.
The intrigueing thing about a vegan diet is that is that it is close to insufficiency for some nutrients, & can be easily manipulated to be restrictive for, say, an essential amino acid. Perhaps someone will one day come up with a vegan diet tailored for PCa.
McCarty suggests eating a "plant-based diet relatively low in bioavailable phosphate and calcium".
My (omnivore) approach has been:
- avoid deli meats with phosphates
- ditto soft drinks
- limit portion size for fish & meat, because of phosphorus content
- avoid dairy
- do not use calcium supplements
Note that both are vital nutrients & cannot be eliminated entirely from the diet.
For more on FGF23, see [2]. It is a full-text link.
-Patrick
[1] ncbi.nlm.nih.gov/pubmed/281...
Med Hypotheses. 2017 Feb;99:68-72. doi: 10.1016/j.mehy.2017.01.001. Epub 2017 Jan 3.
Plant-based diets relatively low in bioavailable phosphate and calcium may aid prevention and control of prostate cancer by lessening production of fibroblast growth factor 23.
McCarty MF1.
Author information
Abstract
Fibroblast growth factor 23 (FGF23), a hormonal regulator of phosphate and vitamin D metabolism produced primarily in bone by osteocytes and mature osteoblasts, is now known to have growth factor activity for many prostate cancers. In some of these cancers, autocrine production of FGF23 drives their proliferation. FGF23 synthesized within bone likely promotes the expansion of prostate cancer bone metastases. Hence, dietary or lifestyle factors which boost bone's production of FGF23 may encourage the induction and spread of prostate cancer. High dietary intakes of bioavailable phosphorus and of calcium have been found to boost FGF23 levels, and this accords well with prospective epidemiology pointing to high intakes of both phosphate and calcium as risk factors for aggressive prostate cancer. Hence, prospective studies correlating baseline FGF23 levels with subsequent risk for prostate cancer, or advanced prostate cancer, are needed. Natural plant-based diets, though not inherently low in calcium or phosphorus, provide forms of these that are less bioavailable than those in animal products, and hence may be expected to down-regulate bone's production of FGF23. This may play a role in the lower risk for clinical prostate cancer observed in vegans and quasi-vegan cultures. Other factors, such as decreased IGF-I levels and mTORC1 activity, may also play a role in this regard.
Copyright © 2017 Elsevier Ltd. All rights reserved.
KEYWORDS:
Calcium; FGF23; Phosphate; Plant-based diet; Prostate cancer; Vegan
PMID: 28110703 DOI: 10.1016/j.mehy.2017.01.001
[PubMed - in process]
[2] ncbi.nlm.nih.gov/pmc/articl...
Oncotarget. 2015 Jul 10;6(19):17291-301.
FGF23 promotes prostate cancer progression.
Feng S1, Wang J1, Zhang Y2, Creighton CJ2,3, Ittmann M1.
Author information
1Department of Pathology and Immunology, Baylor College of Medicine and Michael E. DeBakey Dept. of Veterans Affairs Medical Center, Houston, Texas, USA.
2Dan L. Duncan Cancer Center Division of Biostatistics, Baylor College of Medicine, Houston, Texas, USA.
3Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
Abstract
Prostate cancer is the most common cancer in US men and the second leading cause of cancer deaths. Fibroblast growth factor 23 (FGF23) is an endocrine FGF, normally expressed by osteocytes, which plays a critical role in phosphate homeostasis via a feedback loop involving the kidney and vitamin D. We now show that FGF23 is expressed as an autocrine growth factor in all prostate cancer cell lines tested and is present at increased levels in prostate cancer tissues. Exogenous FGF23 enhances proliferation, invasion and anchorage independent growth in vitro while FGF23 knockdown in prostate cancer cell lines decreases these phenotypes. FGF23 knockdown also decreases tumor growth in vivo. Given that classical FGFs and FGF19 are also increased in prostate cancer, we analyzed expression microarrays hybridized with RNAs from of LNCaP cells stimulated with FGF2, FGF19 or FGF23. The different FGF ligands induce overlapping as well as unique patterns of gene expression changes and thus are not redundant. We identified multiple genes whose expression is altered by FGF23 that are associated with prostate cancer initiation and progression. Thus FGF23 can potentially also act as an autocrine, paracrine and/or endocrine growth factor in prostate cancer that can promote prostate cancer progression.
KEYWORDS:
FGF23; endocrine fibroblast growth factors; fibroblast growth factors; prostate cancer; signal transduction
PMID: 26019137 PMCID: PMC4627308 DOI: 10.18632/oncotarget.4174
[PubMed - indexed for MEDLINE] Free PMC Article